Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22029384 | 1.00 | HDAC8 (0.41) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL31682038 | 1.00 | HDAC8 (0.41) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL29223514 | 1.00 | HDAC8 (0.41) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL18530452 | 0.99 | PSMD10 (0.40) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL28350869 | 0.96 | HDAC8 (0.39) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL20305525 | 0.96 | HDAC8 (0.39) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL3483301 | 0.95 | PSMD10 (0.41) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL20305546 | 0.93 | HDAC8 (0.38) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL31640131 | 0.91 | STAT3 (0.37) | HDAC8PSMD10STAT3ALDH1A1KMT2A | |
| SCHEMBL26917687 | 0.91 | PSMD10 (0.38) | PSMD10STAT3ALDH1A1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685601-A | Androgen receptor binding molecules and uses thereof | 财团法人工业技术研究院 | 2022-07-01 | — | — | CN | disclosed |
| CN-113646002-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degradation compounds and methods of use | 上海睿跃生物科技有限公司 | 2021-11-12 | — | — | CN | disclosed |
| US-6908989-B2 | Process for the production of perbenzylated 1-O-glycosides | SCHERING AG (DE) | 2005-06-21 | — | — | US | disclosed |
| US-6545135-B2 | Alkylation | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-04-08 | — | — | US | disclosed |
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-03-20 | — | — | US | disclosed |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | SCHERING AKTIENGESELLSCHAFT | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055242-A1 | Process for the production of perbenzylated 1-O-glycosides | MAN1B1, STT3B, OSTC | HDAC8 3931/4885PSMD10 2687/4885STAT3 2885/4885 |
| US-20020002274-A1 | Process for the production of perbenzylated 1-0-glycosides | STT3B, MAN1B1, OSTC | HDAC8 3883/4885PSMD10 2534/4885STAT3 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.